{
  "hash": "a28606dff2a0c9ef7a6232e27f78795a",
  "result": {
    "markdown": "---\nformat:\n  revealjs:\n    touch: true\n    controls: true\n    transition: fade\n    transition-speed: fast\n    scrollable: true\n    slide-number: false\n    incremental: true\n    multiplex: true\n    chalkboard: true\n    theme: [default, custom.scss]\nbibliography: references.bib\n---\n\n\n## Principles and Complexity of Antifungal Therapy {background-image=\"aspergillus.png\"}\n\n<br> <br>\n\n<br>\n\n<br>\n\n<br> <br>\n\n<left>**Russell E. Lewis, Pharm.D., FCCP** <br> Associate Professor of Medicine, Infectious Diseases <br> Department of Medical and Surgical Sciences <br> Infectious Diseases Unit- IRCCS S. Orsola University Hospitals <br> Alma Mater Studiorum Università di Bologna <br> Bologna, Italy</left>\n\n## Disclosures\n\n<br>\n\n-   Research funding: Merck & Co Inc., Gilead Sciences\n-   Speaking: Avir, Gilead\n-   Consultancy: F2G, Scynexis, Gilead Sciences, Cidara Therapeutics\n\n## Antifungal timeline\n\n\n::: {.cell}\n::: {.cell-output-display}\n```{=html}\n<div id=\"htmlwidget-9c4ea36e84edfb735ac2\" class=\"timevis html-widget\" style=\"width:960px;height:480px;\">\n<div class=\"btn-group zoom-menu\">\n<button type=\"button\" class=\"btn btn-default btn-lg zoom-in\" title=\"Zoom in\">+</button>\n<button type=\"button\" class=\"btn btn-default btn-lg zoom-out\" title=\"Zoom out\">-</button>\n</div>\n</div>\n<script type=\"application/json\" data-for=\"htmlwidget-9c4ea36e84edfb735ac2\">{\"x\":{\"items\":[{\"start\":\"1955-01-01\",\"content\":\"nystatin\",\"group\":\"Polyene\",\"id\":\"1\"},{\"start\":\"1959-01-01\",\"content\":\"amphotericin B-deoxycholate\",\"group\":\"Polyene\",\"id\":\"2\"},{\"start\":\"1960-01-01\",\"content\":\"griseofulvin\",\"group\":\"Other\",\"id\":\"3\"},{\"start\":\"1967-01-01\",\"content\":\"flucytosine\",\"group\":\"Other\",\"id\":\"4\"},{\"start\":\"1971-01-01\",\"content\":\"miconazole\",\"group\":\"Azole\",\"id\":\"5\"},{\"start\":\"1976-01-01\",\"content\":\"ketoconazole\",\"group\":\"Azole\",\"id\":\"6\"},{\"start\":\"1990-01-01\",\"content\":\"fluconazole\",\"group\":\"Azole\",\"id\":\"7\"},{\"start\":\"1992-01-01\",\"content\":\"itraconazole\",\"group\":\"Azole\",\"id\":\"8\"},{\"start\":\"1991-01-01\",\"content\":\"terbinafine\",\"group\":\"Other\",\"id\":\"9\"},{\"start\":\"1995-01-01\",\"content\":\"amphotericin B lipid complex\",\"group\":\"Polyene\",\"id\":\"10\"},{\"start\":\"1996-01-01\",\"content\":\"liposomal amphotericin B\",\"group\":\"Polyene\",\"id\":\"11\"},{\"start\":\"1997-01-01\",\"content\":\"amphotericin B colloidal dispersion\",\"group\":\"Polyene\",\"id\":\"12\"},{\"start\":\"1999-01-01\",\"content\":\"caspofungin\",\"group\":\"Echinocandin\",\"id\":\"13\"},{\"start\":\"2002-01-01\",\"content\":\"voriconazole\",\"group\":\"Azole\",\"id\":\"14\"},{\"start\":\"2005-01-01\",\"content\":\"micafungin\",\"group\":\"Echinocandin\",\"id\":\"15\"},{\"start\":\"2006-01-01\",\"content\":\"anidulafungin\",\"group\":\"Echinocandin\",\"id\":\"16\"},{\"start\":\"2006-01-01\",\"content\":\"posaconazole\",\"group\":\"Azole\",\"id\":\"17\"},{\"start\":\"2015-01-01\",\"content\":\"isavuconazole\",\"group\":\"Azole\",\"id\":\"18\"},{\"start\":\"2014-01-01\",\"content\":\"posaconazole IV, tablet\",\"group\":\"Azole\",\"id\":\"19\"},{\"start\":\"2021-01-01\",\"content\":\"ibrexafungerp\",\"group\":\"Echinocandin\",\"id\":\"20\"}],\"groups\":[{\"id\":\"Polyene\",\"content\":\"Polyene\"},{\"id\":\"Other\",\"content\":\"Other\"},{\"id\":\"Azole\",\"content\":\"Azole\"},{\"id\":\"Echinocandin\",\"content\":\"Echinocandin\"}],\"showZoom\":true,\"zoomFactor\":0.5,\"fit\":true,\"options\":[],\"height\":null,\"timezone\":null,\"api\":[]},\"evals\":[],\"jsHooks\":[]}</script>\n```\n:::\n:::\n\n\n## What Factors Drive Success of Antifungal Therapy?\n\n<br>\n\nDisease\n\nCurrent/future therapies\\*\n\nSurvival <br> (5 year)\n\nHairy cell leukemia\n\nCladarabine + gemtuzumab ozogamicin (GO)\n\n90%\n\nAcute premyelocytic leukemia\n\nATRA + arsenic ± GO\n\n80-90%\n\nAML (core binding factor positive)\n\nFLAG-GO ± IDA, alloHSCT if MRD positive, if indicated, oral AZA/HMA with venetoclax or FLT3/IDH or menin inhibitors\n\n80-90%+\n\nAML <br>(younger fit)\n\nFLAG-IDA and venetoclax, CLIA and venetoclax\n\n50-60%\n\nAML <br> (older, unfit, complex karyotype, T-53 mutations, MECOM)\n\nLow-intensity triple nucleosides (cladarabine, cytarabine and HMAs + venetoclax; HMAs + venetoclax + targeted therapy\n\n40-50%\n\nALL \\< 60 years\n\nHyperCVAD + CD19/CD20 targeted antibodies\n\n60-70%\n\nALL \\> 60 years\n\nMini-hyper CVAD+ inotuzumab; blinatumab + ponatinib\n\n50%\n\nPh-positive ALL\n\nHyperCVAD + ponatinib; blinatumab + ponatinib\n\n70-80%?\n\n[@kantarjian2021; @kantarjian2022J] <br>\n\n\\*some therapies investigational or not licensed in Canada\n\nDisease\n\nCurrent/ future therapy\\*\n\nSurvival <br>(5 year)\n\nCML\n\nBCR-Abl1 tyrosine kinase inhibitors (imatinib, dasatinib, bosutinib, nilotunib, ponatinib), alloHSCT\n\n85-90%\n\nCLL\n\nIbrutinib, other BTKIs (acalabrutinib, zanubrutinib, pirtobrutinib)\n\n80-90% +\n\nMDS\n\nParenteral HMAs, oral HMAs, venetoclax, others\n\n40% +\n\n[@kantarjian2021; @kantarjian2022J] <br>\n\n\\*some therapies investigational or not licensed in Canada\n\n<br> <br> <br> <br> <br>How is invasive fungal disease risk altered <br> by targeted therapies?\n\nUnexpected consequences of targeted therapy?\n\n<br>\n\n[@burger2015; @chamilos2018]\n\nIbrutinib-associated aspergillosis\n\n<br>\n\n<br>\n\n<br>\n\nRetrospective French surveillance study identified 33 cases of aspergillosis in ibrutinib-treated patients with CLL\n\nCNS aspergillosis in 11/27 (40%), most cases within 3 months of starting therapy\n\nAll patients had refractory/relapsed CLL and other predisposing risk factors\n\n[@ghez2018; @chamilos2018]\n\nFungal infections in patients receiving <br> ibrutinib for lymphoid cancers\n\n<center>Data from MSKCC, New York</center>\n\n<br> <br>\n\nIn a second, retrospective study from MDACC (2014-2018):\n\n21 (2.5%) with proven/probable invasive mold infection\n\nPrimarily pneumonia\n\nMostly Aspergillus spp.\n\nRisk factors: monocytopenia, ≥ 3 prior CLL therapies\n\n[@varughese2018; @frei2020J]\n\n[@bruggemann2022; @stemler2022J]\n\nManaging fungal infection risks with <br> novel therapies for AML\n\nEHA consensus recommendations\n\n<br>\n\nSystematic review of the literature, recommendations developed using GRADE framework (4977 publications evaluated)\n\nOutcomes evaluated:\n\nIncidence of invasive fungal disease (IFD)\n\nProlongation of hospitalization\n\nDays spent in ICU/mortality associated with IFD\n\nPotential DDIs\n\nEvidence-based recommendations were developed for hypomethylating agents (HMAs), FLT-3 inhibitors, and venetoclax-HMA combinations\n\n[@stemler2022J]\n\nSummary of EHA recommendations-1\n\n<br>\n\nHypomethylating agent monotherapy:\n\nStandard use or prophylaxis not recommended\n\nRisk of IFI increased in patients with neutropenia at onset of treatment, prior intensive chemotherapy → conditional recommendation for prophylaxis\n\nFLT3 inhibitors (midostaurin, gilteritinib)\n\nAntifungal prophylaxis recommended during induction chemotherapy\n\nConditional recommendation for prophylaxis during consolidation in patients with risk factors (prior IFI, prolonged neutropenia)\n\nLack of clear medical guidance for managing drug interactions\n\nClose monitoring favoured over empiric FLT-3 inhibitor dose reduction\n\n[@stemler2022J]\n\nSummary of EHA recommendations-2\n\n<br>\n\nVenetoclax\n\nRisk of IFI increased in patients with neutropenia at onset of treatment, prior intensive chemotherapy, or prolonged neutropenia with venetoclax\n\nConditional recommendation to administer prophylaxis\n\nCareful management of drug interactions with triazoles\n\n[@stemler2022J]\n\nVenetoclax dose-adjustment with triazoles\n\n<br>\n\n<center>\n\nVenetoclax + hypomethylating agents for AML;\n\nCo-administration with posaconazole ↑ venetoclax AUC 8-fold\n\n</center>\n\n<br>\n\nDay\n\nFull dose\n\nModerate CYP3A4 inhibitor\n\nStrong CYP3A4 inhibitor\n\nDay 1\n\n100 mg\n\n50 mg\n\n10 mg\n\nDay 2\n\n200 mg\n\n100 mg\n\n20 mg\n\nDay 3\n\n400 mg\n\n200 mg\n\n50 mg\n\nDay 4-28\n\n400 mg\n\n200 mg\n\n70 mg\n\n[@stemler2022J; @bhatnagar2021J]\n\nTriazole prophylaxis increases duration of thrombocytopenia but not neutropenia or infections with dose-adjusted venetoclax\n\n<br>\n\n[@rausch2019]\n\nCYP450 Interactions: The achilles heel of triazoles\n\n<center>75-85% of patients receiving mold-active triazoles have serious drug interactions</center>\n\n<br>\n\n[@bruggemann2009a; @andes2016]\n\nPK/PD Properties of Small Molecule Kinase Inhibitors\n\n<br> <br>\n\nDrug\n\nVenetoclax\n\nMidostraurin\n\nGilteritinib\n\nIvosidenib\n\nEnasidinib\n\nGlasdegib\n\nSpecificity (targets)\n\nBCL2\n\nFLT3\n\nFLT3\n\nIDH1\n\nIDH2\n\nHedgehog pathway\n\nHepatic\n\nCYP3A4\n\nCYP3A4\n\nCYP3A4/5\n\nCYP3A4/5\n\nMultiple CYP enzymes including CYP3A4\n\nCYP3A4/5\n\nEfflux\n\nSubstrate of PgP, BCRP\n\nNot a substrate\n\nSubstrate of PgP, not BCRP, OATP\n\nSubstrate PgP, but not BRCP\n\nNot a substrate of BCRP pr PgP\n\nSubstrate for PGP, BCRP\n\n[@megias-vericat2020J]\n\nToxicities of small-molecule kinase inhibitors\n\n[@wang2020a]\n\nJust avoid triazoles?\n\n<br>\n\nThe problems with echinocandin prophylaxis\n\n<br>\n\n[@gomes2014]\n\n<br> <br> <br> <br> <br> Is their a unique role for isavuconazole <br> vs. other triazoles?\n\nStrong opinions about voriconazole\n\nPharmacokinetic complexity of voriconazole\n\n<br>\n\n[@trifilio2014]\n\nTriazole toxicities\n\n<br>\n\n[@Lewis2011805; @johnson2021]\n\n<br>\n\n[@ostrosky-zeichner2022J]\n\nTriazole safety\n\n<br>\n\nMulticenter registry of prophylaxis (n=1777) and treatment (n=816) courses\n\nAdverse effects leading to treatment discontinuation:\n\nvoriconazole (n=494) 14.2%\n\nposaconazole (n=547) 11.3%\n\nisavuconazole (n=514) 3.9%\n\nmultiple/sequenced therapy (n=454) 11.7%\n\nQTc prolongation was rare, but more frequent with voriconazole and posaconazole\n\nSevere drug interactions occurred in 4% of all treated patients\n\nIFI mortality rates were similar for all agents ranging between 1.1-1.8%\n\n[@ostrosky-zeichner2022J]\n\nWhat makes isavuconazole <br>(isavuconazonium) unique?\n\n<br>\n\n<br>\n\nBroad spectrum of activity\n\nProdrug IV/ oral formulations (\\> 90% bioav.)\n\nPredictable linear PK, t1/2=130h\n\nLess need for TDM\n\nBetter safety profile than voriconazole\n\nLess potent CYP3A4/5 inhibition\n\nLess cutaneous, CNS, hepatic toxicities\n\nDoes not prolong QT\n\n[@johnson2021; @maertens2016]\n\nQT prolongation risk with triazoles\n\n<br>\n\n<br>\n\n<br>\n\nOlder triazoles inhibit human ether-a-go-go (hERG) channel, which underlies rapid K+ rectifier current\n\nIsavuconazole shortens cardiac QT in a dose-related manner, with no associated cardiac risk\n\nhCav1.2 L-type Ca++ channels\n\n[@keirns2017]\n\nIsavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE)\n\n<br>\n\n[@maertens2016]\n\nTreatment-emergent adverse effects <br> in the SECURE trial\n\n<br>\n\nOverall drug-related AE (VOR-60% vs. ISA-42%, p\\<0.001)\n\nHepatobiliary disorders (VOR-16% vs. ISA-9%, p=0.016)\n\nVisual disturbances (VOR-27% vs. ISA-15%, p=0.002)\n\nSkin or subcutaneous tissue (VOR-42% vs. ISA-33%, p=0.037\n\n[@maertens2016]\n\nIsavuconazole treatment for mucormycosis: <br> a single-arm, open-label, case-control study (VITAL)\n\n[@marty2014]\n\nIsavuconazole drug interaction potential in HSCT\n\n<br>\n\nDrug\n\nPharmacokinetic change\n\nInitial management\n\nTacrolimus\n\n↑ AUC 1.8-3xfold\n\n↑ Cmax 1.4-2.8xfold\n\n40-50% reduction in tacrolimus dose, TDM. <br>Some case series suggest no empiric dose reduction was required\n\nPrednisone or Prednisolone\n\n↑ AUC (8%) minimal\n\nNo dose adjustments recommended\n\nRuxolitinib\n\n↑AUC and Cmax by an average of 27% and 8%\n\nAlthough dose reduction is recommended for strong CYP3A4 inhibitors, no dose reduction recommended with moderate inhibitors such as isavuconazole\n\n[@kufel2018; @kieu2019; @groll2017b; @ouatas2017]\n\nIsavuconazole drug interaction potential\n\n<br>\n\nDrug\n\nPharmacokinetic change\n\nInitial management\n\nVenetoclax\n\n↑AUC 2-3.9xfold\n\nDose reduction of venetoclax by 50%\n\nMidostaurin\n\n↑AUC 1.44xfold higher\n\nAvoid strong CYP3A4 inhibitors, no dose reduction recommended for moderate CYP3A4 inhibitors\n\nGilteritinib\n\n↑AUC 1.4xfold; <br>\n\n↑Cmax 1.2-fold higher\n\nAvoid strong CYP3A4 inhibitors, no dose reduction recommended for moderate CYP3A4 inhibitors\n\n[@kufel2018; @kieu2019; @groll2017b; @ouatas2017]\n\nDoes TDM support claims of less potent <br> CYP3A4 inhibition?\n\n[@Menna2021-mb]\n\n[@bose2020]\n\n[@bose2020]\n\n[@bose2020]\n\n[@bose2020]\n\nIsavuconazole tolerability\n\n<br>\n\n<br>\n\nPosaconazole experience <br> (previous study with tablet/IV)\n\nGrade III/IV liver injury with tablet and IV formulations (9%)\n\nPrimary hyperbilirubinemia\n\nHigher frequency in patients with POS serum levels \\> 1,830 ng/mL\n\nIsavuconazole (current study)\n\nGrade 1 transaminitis (2.7%)\n\nGrade 2 elevated T. bilirubin (1.3%)\n\nNo elevations in QTc detected vs. baselines at 10 days\n\n\"Isavuconazole was well tolerated and facilitated use of the most potent molecular-targeted agents in remission-induction chemotherapy with excellent short term survival and high remission rates.\"\n\n[@bose2020; @Tverdek2017-gh]\n\ndd\n\n<br>\n\n<br>\n\n[@Young2021-jx]\n\nJo-Anne H. Young, Clin Infect Dis 2021\n\n<br>\n\n<br>\n\n\"This is the first antifungal prophylaxis study in this select population of patients with leukemia, specifically, those patients being treated with the BCL-2 antagonist venetoclax and fms3-like tyrosine kinase 3 (FLT3) inhibitors.\n\n<br>\n\n\"Clinicians should take away from these studies the fact that many of the advanced-generation azoles can be used interchangeably in times of prophylaxis when they are needed.\"\n\nSummary\n\n<br>\n\nKnowledge of fungal infection risk with targeted therapy is evolving, and depends heavily on the individual patient treatment scenario <br>\n\nMany small molecule inhibitors are metabolised by CYP3A4/5 and have potential for QTc prolongation, making concurrent use with broad-spectrum triazoles difficult <br>\n\nIsavuconazole has several unique pharmacokinetic and safety advantages over older triazoles, making it an useful alternative in patients receiving targeted therapies\n\nThank you for your attention!\n\nReferences\n\n<br>\n\nAll figures created by R. Lewis using www.biorender.com <br> <br>\n",
    "supporting": [
      "Exeter_files"
    ],
    "filters": [
      "rmarkdown/pagebreak.lua"
    ],
    "includes": {
      "include-in-header": [
        "<script src=\"Exeter_files/libs/htmlwidgets-1.5.4/htmlwidgets.js\"></script>\n<link href=\"Exeter_files/libs/visjs-7.4.9/vis-timeline-graph2d.min.css\" rel=\"stylesheet\" />\n<script src=\"Exeter_files/libs/visjs-7.4.9/vis-timeline-graph2d.min.js\"></script>\n<link href=\"Exeter_files/libs/timeline-0.4/timevis.css\" rel=\"stylesheet\" />\n<script src=\"Exeter_files/libs/timevis-binding-2.0.0/timevis.js\"></script>\n<script src=\"Exeter_files/libs/jquery-3.6.0/jquery-3.6.0.min.js\"></script>\n"
      ],
      "include-after-body": [
        "\n<script>\n  // htmlwidgets need to know to resize themselves when slides are shown/hidden.\n  // Fire the \"slideenter\" event (handled by htmlwidgets.js) when the current\n  // slide changes (different for each slide format).\n  (function () {\n    function fireSlideChanged(previousSlide, currentSlide) {\n\n      // dispatch for htmlwidgets\n      const event = window.document.createEvent(\"Event\");\n      event.initEvent(\"slideenter\", true, true);\n      window.document.dispatchEvent(event);\n\n      // dispatch for shiny\n      if (window.jQuery) {\n        if (previousSlide) {\n          window.jQuery(previousSlide).trigger(\"hidden\");\n        }\n        if (currentSlide) {\n          window.jQuery(currentSlide).trigger(\"shown\");\n        }\n      }\n    }\n\n    // hookup for reveal\n    if (window.Reveal) {\n      window.Reveal.addEventListener(\"slidechanged\", function(event) {\n        fireSlideChanged(event.previousSlide, event.currentSlide);\n      });\n    }\n\n    // hookup for slidy\n    if (window.w3c_slidy) {\n      window.w3c_slidy.add_observer(function (slide_num) {\n        // slide_num starts at position 1\n        fireSlideChanged(null, w3c_slidy.slides[slide_num - 1]);\n      });\n    }\n\n  })();\n</script>\n\n"
      ]
    },
    "engineDependencies": {},
    "preserve": {},
    "postProcess": true
  }
}